(Q44797478)

6 December 2017

title

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy (English)

1 reference

Enteroaggregative Escherichia coli

6 December 2017

0 references

1 reference

1 reference

8

Herbert L DuPont

1 reference

6 December 2017

7

David A Sack

1 reference

6 December 2017

Rosa M Infante

1

1 reference

6 December 2017

Charles D Ericsson

2

1 reference

6 December 2017

Zhi-Dong Jiang

3

1 reference

6 December 2017

Shi Ke

4

1 reference

6 December 2017

Robert Steffen

5

1 reference

6 December 2017

Lise Riopel

6

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Clinical Gastroenterology and Hepatology

6 December 2017

published in

1 reference

6 December 2017

volume

2

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

135-138

1 reference

Risk and aetiology of diarrhoea at various tourist destinations

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Therapy of travelers' diarrhea with rifaximin on various continents

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Association of Escherichia coli HEp-2 adherence patterns with type and duration of diarrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

HEp-2 cell-adherent Escherichia coli in patients with human immunodeficiency virus-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Detection of enteroaggregative Escherichia coli with formalin-preserved HEp-2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900322-7

7 January 2021

10.1016/S1542-3565(03)00322-7

Identifiers

DOI

1 reference

6 December 2017

1 reference